Multicentric Castleman Disease

  • Mark N. Polizzotto
  • Thomas S. Uldrick
  • Robert Yarchoan
Chapter

Abstract

Multicentric Castleman disease is a systemic disorder of lymph nodes characterized by inflammatory symptoms including fever, night sweats, cachexia, malaise, and lymphadenopathy together with laboratory abnormalities including anemia and hypoalbuminemia. These symptoms may be life-threatening. The diagnosis is based on specific pathological findings in affected lymph nodes. In individuals infected with HIV, multicentric Castleman disease is almost exclusively caused by infection with a cancer-causing herpesvirus, Kaposi sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8). This may be considered a separate entity from the non-KSHV related or idiopathic form of multicentric Castleman disease and from unicentric forms of Castleman disease. While these disorders have pathological and clinical similarities, the KSHV-related form is distinguished by its pathological characteristics and unique viral etiology.

References

  1. Aoki Y, Tosato G. Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol. 2007;312:309–26.PubMedGoogle Scholar
  2. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood. 2001;97:2526.PubMedCrossRefGoogle Scholar
  3. Beukes CA, Thiart J. The incidence of human herpes virus-8 expression in lymph node biopsies from human immunodeficiency virus-positive patients. Histopathology. 2012;61:942–4.PubMedCrossRefGoogle Scholar
  4. Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL, Siani MA, Sasaki T, Williams TJ, Gray PW, Moore PS, Chang Y, Weiss RA. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science. 1997;278:290–4.PubMedCrossRefGoogle Scholar
  5. Boulanger MJ, Chow D, Brevnova E, Martick M, Sandford G, Nicholas J, Garcia KC. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J Mol Biol. 2004;335:641–54.PubMedCrossRefGoogle Scholar
  6. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415–21.PubMedCrossRefGoogle Scholar
  7. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147:836–9.PubMedCrossRefGoogle Scholar
  8. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, Boffito M, Gazzard B, Nelson M. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS. 2009;23:1701–6.PubMedCrossRefGoogle Scholar
  9. Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B, Stebbing J, Nelson M. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29:2481–6.PubMedCrossRefGoogle Scholar
  10. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood. 2004a;103:1632–4.PubMedCrossRefGoogle Scholar
  11. Casper C, Redman M, Huang ML, Pauk J, Lampinen TM, Hawes SE, Critchlow CW, Morrow RA, Corey L, Kiviat N, Wald A. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr. 2004b;35:233–8.PubMedCrossRefGoogle Scholar
  12. Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198:23–30.PubMedCentralPubMedCrossRefGoogle Scholar
  13. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250:1001–5.PubMedCrossRefGoogle Scholar
  14. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–30.PubMedCrossRefGoogle Scholar
  15. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–91.PubMedCrossRefGoogle Scholar
  16. Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, Chang Y, Knowles DM. Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol. 1996;70:8218–23.PubMedCentralPubMedGoogle Scholar
  17. Chadburn A, Hyjek EM, Tam W, Liu Y, Rengifo T, Cesarman E, Knowles DM. Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). Histopathology. 2008;53:513–24.PubMedCrossRefGoogle Scholar
  18. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266: 1865–9.PubMedCrossRefGoogle Scholar
  19. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–46.PubMedCrossRefGoogle Scholar
  20. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R. Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi’s sarcoma-associated herpesvirus infected cells. Cancer Res. 2007;67:7003–10.PubMedCrossRefGoogle Scholar
  21. DiGiovanna JJ, Safai B. Kaposi’s sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. Am J Med. 1981;71:779–83.PubMedCrossRefGoogle Scholar
  22. Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, Meignin V, Oksenhendler E, Boshoff C, Isaacson PG. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–6.PubMedCrossRefGoogle Scholar
  23. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12.PubMedGoogle Scholar
  24. Friborg J, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999;402:889–94.PubMedGoogle Scholar
  25. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69:86–90.PubMedGoogle Scholar
  26. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB trial. J Clin Oncol. 2007;25:3350–6.PubMedCrossRefGoogle Scholar
  27. Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119:2228–33.PubMedCrossRefGoogle Scholar
  28. Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood. 2012;119:5078–87.PubMedCrossRefGoogle Scholar
  29. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297–314.PubMedCentralPubMedGoogle Scholar
  30. Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma [letter]. Lancet. 1993;342:497.PubMedCrossRefGoogle Scholar
  31. Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118: 3499–503.PubMedCrossRefGoogle Scholar
  32. Hu F, Nicholas J. Signal transduction by human herpesvirus 8 viral interleukin-6 (vIL-6) is modulated by the nonsignaling gp80 subunit of the IL-6 receptor complex and is distinct from signaling induced by human IL-6. J Virol. 2006;80:10874–8.PubMedCentralPubMedCrossRefGoogle Scholar
  33. Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, William DC, Laubenstein LJ. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet. 1981;2:598–600.PubMedCrossRefGoogle Scholar
  34. Jenner RG, Alba MM, Boshoff C, Kellam P. Kaposi’s sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol. 2001;75:891–902.PubMedCentralPubMedCrossRefGoogle Scholar
  35. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi’s sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood. 1999;94:2871–9.PubMedGoogle Scholar
  36. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–83.PubMedCrossRefGoogle Scholar
  37. Little RF, Yarchoan R. Poor specific T cell responses to human herpesvirus 8: a key to unleashing Kaposi sarcoma? J Infect Dis. 2006;194:1030–1.PubMedCrossRefGoogle Scholar
  38. Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102:2786–8.PubMedCrossRefGoogle Scholar
  39. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 1999;340:1063–70.PubMedCrossRefGoogle Scholar
  40. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-cancer registry match study. Int J Cancer. 2006;118:985–90.PubMedCrossRefGoogle Scholar
  41. Meads MB, Medveczky PG. Kaposi’s sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J Biol Chem. 2004;279:51793–803.PubMedCrossRefGoogle Scholar
  42. Menke DM, Tiemann M, Camoriano JK, Chang SF, Madan A, Chow M, Habermann TM, Parwaresch R. Diagnosis of Castleman’s disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996;105:268–76.PubMedGoogle Scholar
  43. Moore PS , Chang Y. Kaposi’s sarcoma-associated herpesvirus-encoded oncogenes and oncogenesis. J Natl Cancer Inst Monogr.1998;(23):65–71.Google Scholar
  44. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996a;274:1739–44.PubMedCrossRefGoogle Scholar
  45. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, Pellett PE, McGeoch DJ, Chang Y. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae. J Virol. 1996b;70:549–58.PubMedCentralPubMedGoogle Scholar
  46. Morbidity and Mortality Weekly Report. Kaposi’s sarcoma and pneumocystis pneumonia among homosexual men—New York City. Morb Mortal Wkly Rep. 1981;30:305–8.Google Scholar
  47. Morbidity and Mortality Weekly Report. Diffuse, undifferentiated non-Hodgkins lymphoma among homosexual males–United States. MMWR Morb Mortal Wkly Rep. 1982;31:277–9.Google Scholar
  48. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–56.PubMedGoogle Scholar
  49. Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman-Kien AE, Fleckenstein B. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839–42.PubMedCentralPubMedGoogle Scholar
  50. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMedGoogle Scholar
  51. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–32.PubMedCrossRefGoogle Scholar
  52. Oksenhendler E, Duarte M, Soulier J, Cacoub P, Welker Y, Cadranel J, Cazals-Hatem D, Autran B, Clauvel JP, Raphael M. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61.PubMedCrossRefGoogle Scholar
  53. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96:2069.PubMedGoogle Scholar
  54. Paulose-Murphy M, Ha NK, Xiang C, Chen Y, Gillim L, Yarchoan R, Meltzer P, Bittner M, Trent J, Zeichner S. Transcription program of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus). J Virol. 2001;75:4843–53.PubMedCentralPubMedCrossRefGoogle Scholar
  55. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–32.PubMedCrossRefGoogle Scholar
  56. Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D, Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med. 1990;113:276–82.PubMedCrossRefGoogle Scholar
  57. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi Sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.PubMedCentralPubMedCrossRefGoogle Scholar
  58. Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O’Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;4189:98 [Epub October 30, 2013].Google Scholar
  59. Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood. 2007;110:4132–3.PubMedCrossRefGoogle Scholar
  60. Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.PubMedCrossRefGoogle Scholar
  61. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J. Liposomal daunorubicin treatment of HIV-associated Kaposi’s sarcoma. Lancet. 1993;341:1242–3.PubMedCrossRefGoogle Scholar
  62. Pyakurel P, Massambu C, Castanos-Velez E, Ericsson S, Kaaya E, Biberfeld P, Heiden T. Human herpesvirus 8/Kaposi sarcoma herpesvirus cell association during evolution of Kaposi sarcoma. J AIDS. 2004;36:678–83.Google Scholar
  63. Qin Z, Kearney P, Plaisance K, Parsons CH. Pivotal advance: Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leukoc Biol. 2009;87:25–34.PubMedCentralCrossRefGoogle Scholar
  64. Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72:1005–12.PubMedCentralPubMedGoogle Scholar
  65. Shiels MS, Goedert JJ, Engels EA. Recent trends and future directions in human immunodeficiency virus-associated cancer. Cancer. 2010;116:5344–7.PubMedCentralPubMedCrossRefGoogle Scholar
  66. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753–62.PubMedCentralPubMedCrossRefGoogle Scholar
  67. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80.PubMedGoogle Scholar
  68. Staskus KA, Sun R, Miller G, Racz P, Jaslowski A, Metroka C, Brett-Smith H, Haase AT. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. J Virol. 1999;73:4181–7.PubMedCentralPubMedGoogle Scholar
  69. Stebbing J, Adams C, Sanitt A, Mletzko S, Nelson M, Gazzard B, Newsom-Davis T, Bower M. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood. 2011;118:271–5.PubMedCrossRefGoogle Scholar
  70. Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, Miller G. Kinetics of Kaposi’s sarcoma-associated herpesvirus gene expression. J Virol. 1999;73:2232.PubMedCentralPubMedGoogle Scholar
  71. Teruya-Feldstein J, Zauber P, Setsuda JE, Berman EL, Sorbara L, Raffeld M, Tosato G, Jaffe ES. Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman’s disease and primary effusion lymphoma. Lab Invest. 1998;78:1637–42.PubMedGoogle Scholar
  72. Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51:350–8.PubMedCentralPubMedCrossRefGoogle Scholar
  73. Uldrick TS, Polizzotto MN, Aleman K, O’Mahony D, WyvilL KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R. High-dose Zidovudine Plus Valganciclovir for Kaposi Sarcoma Herpesvirus-associated Multicentric Castleman Disease: A Pilot Study of Virus-activated Cytotoxic Therapy. Blood. 2011;117:6977–86.PubMedCentralPubMedCrossRefGoogle Scholar
  74. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr Opin Oncol. 2012;24:495–505.PubMedCrossRefGoogle Scholar
  75. Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43: 698–704.PubMedCrossRefGoogle Scholar
  76. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74:1360–7.PubMedGoogle Scholar
  77. Ziegler JL, Miner RC, Rosenbaum E, Lennette ET, Shillitoe E, Casavant C, Drew WL, Mintz L, Gershow J, Greenspan J, Becksted J, Yamamoto K. Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet. 1982;2:631–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Mark N. Polizzotto
    • 1
  • Thomas S. Uldrick
    • 1
  • Robert Yarchoan
    • 2
  1. 1.HIV and AIDS Malignancy BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
  2. 2.HIV and AIDS Malignancy Branch and office of HIV and AIDS Malignancy, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations